Compare Rio Tinto (ADR) (RIO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rio Tinto (ADR) vs Tango Therapeutics Inc. — how do they compare? Rio Tinto (ADR) trades at $89.95 (market cap $150.32B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Rio Tinto (ADR) is far larger — about 40.1× Tango Therapeutics Inc.'s market cap, and Rio Tinto (ADR) pays a 5% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rio Tinto (ADR) for 12 Days and Tango Therapeutics Inc. for 0 Days on average.
| RIO | TNGX | |
|---|---|---|
Market Cap | $150.32B | $3.75B |
Volume | 1,444,205 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $112.04 | $32.90 |
52-Week Low | $67.89 | $7.50 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $163.66B | $2.77B |
Dividend Yield | 5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rio Tinto (RIO) trades at $93.06, down 1.31% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company demonstrates strong profitability with 19.58% net income margin and 19.57% ROE, supported by recent quarterly earnings beats. Recent news highlights operational strength with 27% copper production growth at Oyu Tolgoi and maintained 2026 guidance.
The stock presents a compelling value opportunity with a 12.61 P/E ratio trading below the $103.13 consensus target. However, bearish technical momentum and legal risks from Madagascar contamination claims warrant caution. Analyst sentiment is mixed with 35% buy ratings versus 23% sell recommendations, suggesting balanced risk-reward for long-term investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rio Tinto (ADR)
Rio Tinto is a global mining company that produces metals and minerals including iron ore, aluminium, copper, and lithium. Its operations supply materials used in construction, manufacturing, transportation, and energy systems.
Read more on RIO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
